Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Leukemia
|
February 25, 2012
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
J Hoellenriegel, G P Coffey, U Sinha, et al.
Leukemia
|
December 15, 2007
A prognostic score for patients with lower risk myelodysplastic syndrome
G Garcia-Manero, J Shan, S Faderl, et al.
Leukemia
|
April 29, 2015
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
K Balakrishnan, M Peluso, M Fu, et al.
Leukemia
|
January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells
J A Burger, N S Velev, E J Jabbour, et al.
Leukemia
|
February 26, 2011
HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance
N Shah, W K Decker, R Lapushin, et al.
Leukemia
|
November 4, 2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
V K Patel, B Lamothe, M L Ayres, et al.
Leukemia
|
December 27, 2016
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
V M Patel, K Balakrishnan, M Douglas, et al.
Leukemia
|
August 21, 2015
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
F P Tambaro, G Garcia-Manero, S M O'Brien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
P Jain, E Aoki, M Keating, et al.
Journal of Hematology & Oncology
|
February 22, 2026
UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies
Carmela Dell'Aversana, G Sgueglia, C Massaro, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Leukemia
|
February 25, 2012
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
J Hoellenriegel, G P Coffey, U Sinha, et al.
Leukemia
|
December 15, 2007
A prognostic score for patients with lower risk myelodysplastic syndrome
G Garcia-Manero, J Shan, S Faderl, et al.
Leukemia
|
April 29, 2015
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
K Balakrishnan, M Peluso, M Fu, et al.
Leukemia
|
January 8, 2010
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells
J A Burger, N S Velev, E J Jabbour, et al.
Leukemia
|
February 26, 2011
HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance
N Shah, W K Decker, R Lapushin, et al.
Leukemia
|
November 4, 2017
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
V K Patel, B Lamothe, M L Ayres, et al.
Leukemia
|
December 27, 2016
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
V M Patel, K Balakrishnan, M Douglas, et al.
Leukemia
|
August 21, 2015
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
F P Tambaro, G Garcia-Manero, S M O'Brien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
P Jain, E Aoki, M Keating, et al.
Journal of Hematology & Oncology
|
February 22, 2026
UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies
Carmela Dell'Aversana, G Sgueglia, C Massaro, et al.
Page
of 4